Gene transfer by viral vectors into blood vessels in a rat model of retinopathy of prematurity

I Chowers, E Banin, Y Hemo, R Porat, H Falk, E Keshet, J Pe'er, A Panet, I Chowers, E Banin, Y Hemo, R Porat, H Falk, E Keshet, J Pe'er, A Panet

Abstract

Aims: To test the feasibility of gene transfer into hyaloid blood vessels and into preretinal neovascularisation in a rat model of retinopathy of prematurity (ROP), using different viral vectors.

Methods: Newborn rats were exposed to alternating hypoxic and hyperoxic conditions in order to induce ocular neovascularisation (ROP rats). Adenovirus, herpes simplex, vaccinia, and retroviral (MuLV based) vectors, all carrying the beta galactosidase (beta-gal) gene, were injected intravitreally on postnatal day 18 (P18). Two sets of controls were also examined: P18 ROP rats injected with saline and P18 rats that were raised in room air before the viral vectors or saline were injected. Two days after injection, the rats were killed, eyes enucleated, and beta-gal expression was examined by X-gal staining in whole mounts and in histological sections.

Results: Intravitreal injection of the adenovirus and vaccinia vectors yielded marked beta-gal expression in hyaloid blood vessels in the rat ROP model. Retinal expression of beta-gal with these vectors was limited almost exclusively to the vicinity of the injection site. Injection of herpes simplex yielded a punctuate pattern of beta-gal expression in the retina but not in blood vessels. No significant beta-gal expression occurred in rat eyes injected with the retroviral vector.

Conclusions: Adenovirus is an efficient vector for gene transfer into blood vessels in an animal model of ROP. This may be a first step towards utilising gene transfer as a tool for modulating ocular neovascularisation for experimental and therapeutic purposes.

References

    1. Am J Pathol. 1997 Jul;151(1):281-91
    1. Hum Gene Ther. 1996 May 1;7(7):799-808
    1. Ophthalmic Res. 1997;29(5):242-51
    1. Invest Ophthalmol Vis Sci. 1997 Oct;38(11):2224-33
    1. Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):149-51
    1. Hum Gene Ther. 1997 Dec 10;8(18):2239-47
    1. Hum Gene Ther. 1998 Jan 1;9(1):81-6
    1. Am J Pathol. 1998 May;152(5):1359-65
    1. Invest Ophthalmol Vis Sci. 1998 Jun;39(7):1097-106
    1. Anticancer Res. 1998 May-Jun;18(3A):1357-60
    1. Am J Pathol. 1998 Sep;153(3):757-65
    1. Dev Dyn. 1998 Nov;213(3):322-33
    1. Exp Eye Res. 1999 May;68(5):553-63
    1. Am J Pathol. 1999 Jun;154(6):1743-53
    1. Cell. 1999 Oct 1;99(1):13-22
    1. Curr Eye Res. 1997 Jul;16(7):656-62
    1. J Virol. 2000 Apr;74(8):3909-17
    1. Invest Ophthalmol Vis Sci. 1981 Nov;21(5):689-99
    1. Mol Cell Biol. 1985 Dec;5(12):3403-9
    1. J Electron Microsc (Tokyo). 1990;39(1):46-9
    1. J Comp Neurol. 1994 Jan 1;339(1):3-11
    1. Ophthalmic Surg. 1993 Dec;24(12):846-50
    1. Pediatr Res. 1994 Dec;36(6):724-31
    1. Nature. 1995 Jul 6;376(6535):62-6
    1. Gene Ther. 1994 Mar;1(2):122-6
    1. Nat Med. 1995 Oct;1(10):1024-8
    1. Ophthalmology. 1996 Feb;103(2):323-8
    1. Transplantation. 1996 Feb 15;61(3):363-70
    1. Hum Gene Ther. 1996 Aug 20;7(13):1483-90
    1. Hum Gene Ther. 1996 Sep 10;7(14):1763-9
    1. Ophthalmology. 1995 Oct;102(10):1417-24
    1. Science. 1997 Jun 13;276(5319):1706-9
    1. Proc Natl Acad Sci U S A. 1996 May 14;93(10):4851-6
    1. Nat Med. 1996 Jun;2(6):649-54
    1. J Virol. 1996 Aug;70(8):5701-5

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe